| Literature DB >> 35280414 |
Tao Wu1,2, Sha Li1,2, Jing Ren3, Dun Wang1,2, Yanran Ai1,2.
Abstract
Background: Myofascial pain syndrome (MPS) is recurrent local myofascial pain with various treatment methods. In recent years, extracorporeal shock wave therapy (ESWT) has attracted much attention, but its role still lacks systematic review. We included controlled clinical studies for meta-analysis to systematically evaluate the application effect of ESWT.Entities:
Keywords: Extracorporeal shock waves; meta-analysis; myofascial pain syndrome (MPS)
Year: 2022 PMID: 35280414 PMCID: PMC8908187 DOI: 10.21037/atm-22-295
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1The selection flow chart. RCT, randomized control trial; MPS, myofascial pain syndrome; WOS, Web of Science.
Basic characteristics/patient information/outcome indicators/quality scores of the included studies
| Author | Year of publication | Pain site | Mean age (years) | Population (E/C) | Experimental group | Control group | Follow-up time | Outcome indicators | PEDro Score |
|---|---|---|---|---|---|---|---|---|---|
| Jeon | 2012 | Neck and upper back | 45.00±15.46 | 15/15 | ESWT | TPI + TENS | 4 weeks | PPT/VAS/PRS/MPQ | 8 |
| Hong | 2017 | Lumborum | 55.46±15.09 | 15/15 | ESWT | TPI | 4 weeks | PPT/ODI/RM/QBS | 7 |
| Aktürk | 2018 | Neck and upper back | 33.45±8.02 | 20/20 | ESWT | US | 6 weeks | PPT/VAS/SF-36 | 9 |
| Luan | 2019 | Neck and upper back | 32.47±10.58 | 30/32 | ESWT | DN | 4 weeks | PPT/VAS/NDI | 10 |
| Gezgİnaslan | 2019 | Neck and upper back | 44.2±11.94 | 49/45 | H-ESWT | TENS + US | 4 weeks | VAS/SF-36/PSQI/NDI/BDI | 10 |
| Kamel | 2020 | Neck and upper back | 48.8±7.5 | 22/21 | ESWT | US | 4 weeks | VAS/ROM | 10 |
| Toghtamesh | 2020 | Neck and upper back | 28.13±3.98 | 16/16 | ESWT | DN | 4 weeks | VAS/ROM | 10 |
| Rahbar | 2021 | Neck and upper back | 38.09±9.67 | 22/23 | ESWT | US + HP | 4 weeks | VAS/PPT/NDI | 9 |
| Taheri | 2021 | Neck and upper back | 46.6±12.6 | 19/18 | ESWT | US | 4 weeks | VAS/NDI | 8 |
| Yalçın ( | 2021 | Neck and upper back | 40.4±12.8 | 75/82 | ESWT | KT | 4 weeks | VAS/PPT/NDI | 7 |
E, experimental; C, control; PPT, pressure pain threshold; VAS, Visual Analog Scale; MPQ, McGrill pain questionnaire; PRS, Pain Rating Scale; ESWT, extracorporeal shock wave therapy; TPI, trigger point injection; TENS, transcutaneous electrical nerve stimulation; ODI, Oswestry Disability Index; RM, Roles and Maudsley; QBS, Quebec Back Pain Disability Scale scores; SF-36, Short Form-36 for quality of life; US, ultrasound; HP, hot pack; DN, dry needling; NDI, Neck Disability Index; H-ESWT, high-energy flux density ESWT; PSQI, Pittsburgh Sleep Quality Index; BDI, Beck Depression Inventory; ROM, range of motion; KT, kinesiological taping.
Figure 2Summary chart of risk of bias assessment of included literatures (10-19).
Figure 3Risk of bias assessment chart of the included literature.
Figure 4Comparison of pain intensity after ESWT treatment and other modalities for MPS (10,12-19). ESWT, extracorporeal shock wave therapy; MPS, myofascial pain syndrome; SD, standard deviation; CI, confidential interval; IV, inverse variance.
Figure 5Comparison of pain thresholds after ESWT and other modalities for MPS (10-13,17,19). ESWT, extracorporeal shock wave therapy; MPS, myofascial pain syndrome; SD, standard deviation; CI, confidential interval; IV, inverse variance.
Figure 6Neck Disability Index after ESWT treatment and other modalities for MPS (13,17,19). ESWT, extracorporeal shock wave therapy; MPS, myofascial pain syndrome; SD, standard deviation; CI, confidential interval; IV, inverse variance.
Figure 7Funnel plot for the analysis of pain after ESWT and other modalities for MPS. ESWT, extracorporeal shock wave therapy; MPS, myofascial pain syndrome; MD, mean difference; SE, standard error.